• Read more about PREDICT-RT

Short Title: PREDICT-RT

This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score.

Study Number:

GU009

Study Status:

Enrolling

Treatment Agent:

Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide

Resources and Links

National Clinical Trial Identified Number: NCT04513717

Disease:

• Prostate Cancer

Study Phase:

III

ResearchCancer@CooperHealth.edu

Index Extra:

GU, Prostate

Hide from Search:

Off

Physician Name:

• Gary A. Eastwick, MD

Department:

• Radiation Oncology

• Read more about A021806

Short Name: A021806 

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).

Study Number:

A021806

Study Status:

Enrolling

Treatment Agent:

Oxaliplatin Drug, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil

Resources and Links

National Clinical Trial Identified Number: NCT04340141

Disease:

• Pancreatic Cancer

Study Phase:

III

ResearchCancer@cooperhealth.edu

Index Extra:

Pancreatic, GI, gastro

Hide from Search:

Off

Physician Name:

• Jamin C. Morrison, MD, MBA

Department:

• Hematology and Medical Oncology

• Read more about High-Risk Colorectal Cancer Registry Program

The purpose of this registry is to create and maintain a prospective and retrospective database of patients with early-onset colorectal cancer or who are at increased risk for colorectal cancer based on germline gene mutation status, personal history of cancer, and/or family history of cancer.

Study Status:

Enrolling

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: N/A

Disease:

• Colorectal Cancer

Study Phase:

Not Applicable

ResearchCancer@cooperhealth.edu

Index Extra:

GI, Colorectal, gastro

Hide from Search:

Off

Physician Name:

• Steven J McClane, MD, FACS, FASCRS

Department:

• Hematology and Medical Oncology

• Read more about High-Risk Breast Cancer Registry

The purpose of this registry is to collect data on patients at high risk for breast cancer or who have been diagnosed with breast cancer at MD Anderson Cancer Center at Cooper. The importance of the registry is to create a single institution database of individuals (men or women) at increased risk for developing breast cancer or individuals who have had a prior history of breast cancer. The data provided by a site-specific cancer registry can play a significant role in future planning of cancer control programs, in screening and early detection, and in contributing to improved breast cancer care.

Study Status:

Enrolling

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: N/A

Disease:

• Breast Cancer

Study Phase:

Not Applicable

ResearchCancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Catherine E. Loveland-Jones, MD, MS, FACS

Department:

• Breast Cancer Center

• Read more about Financial Toxicity

Short Title: Financial Toxicity

This study investigates the impact of COVID-19 pandemic on out-of-pocket costs, lost wages, and unemployment in patients with breast cancer undergoing breast surgery. Post-mastectomy reconstructive patients are at high risk for financial toxicity (adverse effects of escalating health care cost on well-being). 

Study Number:

PA18-1077

Study Status:

Enrolling

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: NCT04169542

Disease:

• Breast Cancer

Study Phase:

Not Applicable

ResearchCancer@cooperhealth.edu

Index Extra:

breast

Hide from Search:

Off

Physician Name:

• Steven C. Bonawitz, MD, FACS

Department:

• Plastic and Reconstructive Surgery,
• Breast Cancer Center

• Read more about Celestimo

Short Title: Celestimo 

This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior systemic therapy.

 

Study Number:

GO42909

Study Status:

Enrolling

Treatment Agent:

Mosunetuzumab (BTCT4465A, RO7030816), Lenalidomide, Rituximab, Tocilizumab

Resources and Links

National Clinical Trial Identified Number: NCT04712097

Disease:

• Relapsed or Refractory Follicular Lymphoma

Study Phase:

III

ResearchCancer@CooperHealth.edu

Index Extra:

Lymphoma, HEM

Hide from Search:

Off

Physician Name:

• Tulin Budak-Alpdogan, MD

Department:

• Hematology and Medical Oncology

• Read more about SERENA-6

Short Title: SERENA-6

The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib or abemaciclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.

 

Study Number:

D8534C00001

Study Status:

Enrolling

Treatment Agent:

AZD9833

Resources and Links

National Clinical Trial Identified Number: NCT04964934

Disease:

• ER-Positive HER2-Negative Breast Cancer

Study Phase:

III

ResearchCancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Kamel Abou Hussein, MD

Department:

• Breast Cancer Center,
• Hematology and Medical Oncology

• Read more about SAPHIRe

Short Title: SAPHIRe

To compare how often cancer recurs (comes back) after 3 weeks of radiation compared to 5 weeks of radiation in patients who receive radiation therapy delivered to the lymph nodes near the breast. The side effects that can develop during or after radiation treatment, including how often arm swelling (edema) happens, will also be studied.

 

Study Number:

2016-0142

Study Status:

Enrolling

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: NCT02912312

Disease:

• Invasive Breast Cancer

Study Phase:

Not Applicable

ResearchCancer@cooperhealth.edu

Index Extra:

Breast

Hide from Search:

Off

Physician Name:

• Stuti Ahlawat, MD

Department:

• Radiation Oncology

• Read more about Restoring Paul's Life After Cardiac Arrest

Just minutes after Paul made a delivery to a local country club, his heart stopped and he collapsed in the parking lot after suffering from cardiac arrest. When Paul arrived at Cooper, he was in critical condition. His family did not know if he would survive, or if he did, would he be the same man?